低分子肝素钙对晚期肺癌生存时间的影响

The effect of low molecular weight heparin calcium on survival time in patients with advanced lung cancer

目的研究低分子肝素钙对晚期肺癌生存时间的影响。方法收集Ⅳ期非小细胞肺癌和广泛期小细胞肺癌患者的临床资料。所有患者随机分为2组(n=33),对照组仅给予最佳支持治疗,治疗组在最佳支持治疗的基础上予低分子肝素钙皮下注射15天。比较两组生存率差异。结果治疗组的中位生存时间为53天,对照组的中位生存时间为35天,两组的生存率比较有显著差别(P<0.05),在排除ECOG评分因素的影响下,低分子肝素钙治疗对生存时间仍然有显著影响,治疗组较对照组死亡相对危险度为0.30。咯血人数在两组间无显著差异(P>0.05)。结论低分子肝素钙治疗对晚期肺癌的生存时间可能有一定延长作用。

Objective To evaluate the effect of low molecular weight heparin calcium on survival time in patients with advanced lung cancer. Methods 66 patients with advanced lung cancer were included and randomly assigned to two groups. Control group, was given best support therapy and therapy group received a 15-day course of subcutaneous low molecular weight heparin calcium in addition to best support therapy. The primary efficacy analysis was based on time from assignment to death. ECOG score was analyzed by COX propor- tional hazards model. The primary safety outcome was bleeding. Results A median survival time of 53 days was observed in the therapy group and 35 days in the control group, and there was a significant difference（ P 〈 0.05 ）. After adjustment for ECOG score, the treatment effect remained statistically significant. The risk ratio in the therapy group was 0.30 compared with control group. The number of bleeding in the two groups was not different significantly between two groups. Conclusion A brief course of subcutaneous low molecular weight heparin calcium favorably influences the survival in patients with advanced lung cancer.